Citius Pharmaceuticals Inc Dossier - Source-backed chat

Citius Pharmaceuticals Inc

CTXRNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.01

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.54Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $14.8M

Enterprise Value −$2.2M

Shares Outstanding 25.4M diluted

Next Earnings Date5 Apr 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Citius Pharmaceuticals (CTXR) is transitioning from a clinical-stage biopharmaceutical developer to a commercial-stage enterprise. The primary driver of near-term value is its majority-owned subsidiary, Citius Oncology (CTOR), which successfully launched LYMPHIR (denileukin diftitox-cxdl) in December 2025 for relapsed or refractory cutaneous T-cell lymphoma (CTCL). Early launch metrics are highly encouraging, with broad payer coverage and 83% of target accounts already adopting or reviewing the drug. Beyond oncology, Citius's late-stage pipeline is anchored by Mino-Lok, a novel antibiotic lock solution that met its primary endpoints in a pivotal Phase 3 trial and has a clear regulatory pathway following a constructive Type C meeting with the FDA. While the company faces near-term cash runway constraints and dilution risks, its deep pipeline and commercial execution support a highly asymmetric risk-reward profile.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$4.00

High · most bullish analyst$4.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5015%

LYMPHIR commercial sales plateau due to intense competition or slower-than-expected institutional adoption. Regulatory delays push back the Mino-Lok NDA submission, and the company is forced to execute highly dilutive equity raises to fund operations past November 2026, depressing the stock price.

Base CaseCentral scenario

$4.0060%

Matches the consensus mean

LYMPHIR achieves steady commercial traction, transitioning successfully from initial distributor channel fill to sustained patient-driven demand. Citius advances the Mino-Lok NDA submission with the FDA, while managing its cash runway through a combination of strategic debt/equity financing at the subsidiary level and warrant exercises. The stock moves toward the consensus analyst target as regulatory and commercial milestones are met.

Bull CaseUpside scenario

$6.0025%

LYMPHIR commercial uptake accelerates rapidly, capturing a significant share of the $400M+ underserved CTCL market. Concurrently, Citius successfully submits and receives FDA approval for Mino-Lok, establishing it as the first and only FDA-approved treatment to salvage infected central venous catheters. Non-dilutive capital or strategic partnerships fund operations, minimizing shareholder dilution and driving the stock toward the high end of analyst targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Commercial-stage transition with the successful U.S. launch of LYMPHIR in December 2025.
Strong early commercial indicators, including 83% target account formulary penetration and near 100% covered commercial lives.
Mino-Lok Phase 3 trial successfully met primary endpoints, addressing a critical unmet medical need with no approved competitors.
Constructive FDA Type C meeting outlines a clear pathway toward a future NDA submission for Mino-Lok.
Substantial ownership (approx. 71%) in Citius Oncology (CTOR) provides significant equity value.

Key Investment Risks

Limited cash runway, with consolidated cash and cash equivalents of $4.59M as of March 31, 2026, requiring ongoing capital management.
High risk of shareholder dilution from future equity offerings or warrant exercises.
Commercial execution risk associated with the launch of a specialty oncology therapy.
Regulatory risks regarding the final NDA approval of Mino-Lok and Halo-Lido.

Thesis Invalidation Triggers

A flatlining or decline in quarterly LYMPHIR product revenues.
Unexpected FDA refusal to file or clinical hold on the Mino-Lok NDA.
Inability to secure additional financing before the cash runway expires in November 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.